The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Yesterday, the US Food and Drug Administration (FDA) published the following guidances for Abbreviated New Drug Applications (ANDAs) for the generic medicines industry: 25 January 2024
Healthcare giant Johnson & Johnson has reportedly reached a tentative settlement to resolve probes by US states into whether it misled consumers about the safety of its talc products. 24 January 2024
The Serum Institute of India (SII), which claims to be the world’s largest vaccine manufacturer, is joining a growing Coalition for Epidemic Preparedness Innovation (CEPI) network of vaccine producers in the Global South to support more rapid, agile, and equitable responses to future public health disease outbreaks. 24 January 2024
Unnatural Products (UNP), a biotech company pairing AI with chemistry to enable the next generation of molecularly targeted therapeutics, has announced a collaboration with US pharma giant Merck & Co. 24 January 2024
Japanese drugmaker Otsuka Pharmaceutical revealed it has obtained approval in Japan for an additional indication for Rexulti (brexpiprazole) for the treatment of depression/depressive state. 24 January 2024
A new manufacturing plant will be built in Japan, at a cost of over $40 million, by Chinese contract development and manufacturing organization (CDMO) Jiuzhou Pharmaceutical. 24 January 2024
Scientists advising the US medicines regulator will convene to discuss a submission to move Carvykti (ciltacabtagene autoleucel) into an earlier line of treatment. 24 January 2024
Akouos, which Eli Lilly acquired in 2022, has released positive initial clinical results from the Phase I/II AK-OTOF-101 study, testing a gene therapy for the restoration of hearing loss. 24 January 2024
AI specialist BenevolentAI today announced the appointment of Dr Joerg Moeller as chief executive and executive board member with immediate effect. 24 January 2024
The US Court of Appeals for the Second Circuit yesterday affirmed a district court ruling which ordered “pharma bro” Martin Shkreli to face a lifetime ban from participating in the pharmaceutical industry. 24 January 2024
The European Medicines Agency (EMA) has released a major revision of its user guide for micro, small, and medium-sized enterprises (SMEs) in the pharmaceutical sector. 24 January 2024
Accent Therapeutics, a US biopharma seeking to develop a new class of small molecule precision cancer therapies, has announced the completion of a $75 million Series C financing. 23 January 2024
As a market leader in obesity therapy and the largest European company by market cap, Danish diabetes care gain Novo Nordisk has entered into another accord to further solidify its dominance. 23 January 2024
Privately-held Boston, USA-based biotech Vivtex Corporation has entered a research collaboration with Japanese drug major Astellas Pharma. 23 January 2024
Shares of US radiopharmaceuticals-focussed Lantheus Holdings (Nasdaq: LNTH) were down 5.4% at $51.88 by late morning today, as it announced the appointment of Brian Markison, current board chairman and industry veteran, to the position of chief executive (CEO), effective as of March 1, 2024. 23 January 2024
German pharma major Bayer’s independently operated company BlueRock Therapeutics today revealed it has exercised its option to exclusively license OpCT-001 under a 2021 deal with FUJIFILM Cellular Dynamics and Opsis Therapeutics. 23 January 2024